Factor VIII Processing via Proprotein Convertase Co-expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Factor VIII are limited by insufficient endogenous processing enzymes in host cells, which fail to convert all Factor VIII to its processed form, leading to high levels of nonprocessed Factor VIII.
Innovation Solution
Co-expressing Factor VIII with a proprotein convertase, such as proprotein convertase subtilisin/kexin type 5 or 7, in a host cell to cleave Factor VIII at specific residues, thereby increasing the level of processed Factor VIII and decreasing nonprocessed Factor VIII.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If Factor VIII is produced using conventional host cells with endogenous processing enzymes, then the production process is simple, but the level of processed Factor VIII remains insufficient due to inadequate endogenous enzyme activity
Solution Approach 1:
The patent combines the Factor VIII expression system with proprotein convertase enzymes (PC5, PC7, or Furin) in the same host cell. This merging allows the processing enzymes to be co-expressed with Factor VIII, enabling efficient conversion of nonprocessed to processed Factor VIII within the cell, thereby resolving the contradiction between simple production and high processed Factor VIII levels.
Solution Approach 2:
The patent introduces proprotein convertase enzymes as intermediary agents that mediate the conversion of nonprocessed Factor VIII to processed Factor VIII. These convertases act as catalysts that facilitate the cleavage reaction, enabling the system to achieve high processed Factor VIII levels without requiring complex external processing steps.
2Productivity
If proprotein convertase is co-expressed with Factor VIII to increase processed Factor VIII levels, then the processing efficiency improves, but the expression system becomes more complex
Solution Approach 1:
The patent merges Factor VIII and proprotein convertase expression into a unified system where both proteins are co-expressed in the same host cell. This combination allows the processing function to be integrated with production, achieving high productivity while managing complexity through systematic integration rather than separate processing steps.
Solution Approach 2:
The host cell is engineered to self-process Factor VIII by co-expressing the necessary proprotein convertase enzymes within the same cell. This self-service approach eliminates the need for external processing steps, allowing the system to automatically convert nonprocessed to processed Factor VIII, thereby improving productivity without proportionally increasing operational complexity.
3Manufacturing precision
If multiple proprotein convertases are tested for Factor VIII processing, then the optimization of processing efficiency improves, but the screening process becomes more complex
Solution Approach 1:
The patent evaluates different proprotein convertases (PC5, PC7, Furin) for their specific effectiveness in processing Factor VIII, selecting the most appropriate enzyme for the application. This localized optimization approach allows for precise matching of convertase properties to Factor VIII processing requirements, achieving high manufacturing precision while managing screening complexity through focused evaluation of candidate enzymes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the production of processed Factor VIII, ensuring that over 75% of Factor VIII is in its active form, effectively restoring clotting activity to FVIII-deficient plasma.
Implementation Method 1
The Factor VIII may be processed by cleaving Arginine located at amino acid residue 1648 in SEQ ID NO: 6 (full-length Factor VIII), which corresponds to amino acid residue 1667 in SEQ ID NO: 62, or amino acid residue 754 in SEQ ID NO: 2 (B-domain-deleted Factor VIII), which corresponds to amino acid residue 773 in SEQ ID NO: 60.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.